Patient Outcomes Linked to Biomarker Levels with Quantitative Technology

David L. Rimm, M.D., Ph.D Researchers in the Department of Pathology at Yale University School of Medicine report that when using current pathology methods of biomarker detection, the concentration of antibodies used dramatically alters the apparent relationship of biomarker level to clinical outcome. The paper appears in the December issue of the Journal of the National Cancer Institute.